Drug class
CD79b-directed antibody-drug conjugate (ADC); microtubule-disrupting antineoplastic
Mechanism of action
The antibody component binds CD79b on B cells and is internalised. Intracellular linker cleavage releases monomethyl auristatin E (MMAE), which binds microtubules, inhibits cell division and induces apoptosis.
General use cases
- In combination regimens for adults with previously untreated diffuse large B-cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma, according to the applicable product label and treatment setting.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
